Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
| SCBUSSM | ABAGS | |
|---|---|---|
| Held by both | ||
| Ligand Pharmaceuticals | 2.76% | 2.90% |
| Only in SCBUSSM | ||
| 9.08% | N/A | |
| 7.70% | N/A | |
| 6.42% | N/A | |
| 6.12% | N/A | |
| Only in ABAGS | ||
| Q2 | N/A | 2.82% |
| N/A | 2.78% | |
| N/A | 2.78% | |
| ANI Pharmaceuticals | N/A | 2.65% |
30 Dec 2025 → 2 Nov 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| ABAGS | +7.86% | 16.88% | 0.47 |
| SCBUSSM | +5.48% | 30.63% | 0.18 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | SCBUSSM | ABAGS |
|---|---|---|
Fund details | ||
| Fund size | 274 million | 297 million |
| Inception date | 31 May 2016 | 3 Nov 2015 |
| Master fund | กองทุน Granahan US Focused Growth UCITS | abrdn SICAV I - North American Smaller Companies Fund |
| Dividend policy | Does not pay | Does not pay |
Risk and currency hedging | ||
| Risk level | 6 | 6 |
| Hedging policy | Hedged at the manager's discretion | Hedged at the manager's discretion |
| Share hedged | 74.86% | 100.94% |
Minimum purchase and redemption | ||
| First purchase | 1,000 THB | 1,000 THB |
| Subsequent purchase | 1,000 THB | 1,000 THB |
| Redemption (amount) | 1,000 THB | 1,000 THB |
| Redemption (units) | No minimum | 100 units |
| Balance (amount) | 1,000 THB | No minimum |
| Balance (units) | No minimum | 100 units |
Order cut-off and redemption payment | ||
| Buy before | 15:30 | 15:30 |
| Redeem before | 15:30 | 13:00 |
| Redemption paid | T+7 | T+5 |